Biosimilar Candidate CT-P42 in Diabetic Macular Edema: 24-Week Results from a Randomized, Active-Controlled, Phase III Study.

Objective: To demonstrate the therapeutic similarity of CT-P42 compared with reference aflibercept (Eylea) in adult patients with diabetic macular edema (DME).

Design: Randomized, active-controlled, double-masked, phase III clinical trial PARTICIPANTS: Patients with a diagnosis of either type 1 or 2 diabetes mellitus with DME involving the center of the macula.

Methods: Patients were randomized (1:1) to receive either CT-P42 or reference aflibercept (2 mg/0.

Serum autoantibodies against hexokinase 1 manifest secondary to diabetic macular edema onset.

Aims: Autoantibodies against hexokinase 1 (HK1) were recently proposed to be associated with diabetic macular edema (DME). We hypothesized that anti-HK1 autoantibodies can be used as DME markers and to predict DME onset.

Materials And Methods: Serum from patients with 1) DME, 2) diabetes mellitus (DM), 3) allergies or autoimmunities, and 4) control subjects was tested for anti-HK1 and anti-hexokinase 2 (HK2) autoantibodies by immunoblotting.

Randomized Trial of Biosimilar XSB-001 versus Reference Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration.

Objective: To evaluate the efficacy, safety, and immunogenicity of a ranibizumab biosimilar candidate (XSB-001) versus reference product (Lucentis) for neovascular age-related macular degeneration (nAMD).

Design: Phase III, multicenter, randomized, double-masked, parallel-group study.

Participants: Patients with nAMD.

Changes in vascular density in the macula after pars plana vitrectomy for idiopathic macular hole with macular peeling and one type of flap.

Background And Aims: The aim of this study was to evaluate changes in vascular density in the macula after pars plana vitrectomy for idiopathic macular hole (IMD) with macular peeling and flap.

Methods: A prospective study of 35 eyes in 34 patients who had undergone standard surgery. Evaluated parameters were best-corrected visual acuity (BCVA), intraocular pressure (IOP), central macular thickness (CRT), macular volume (TMV) and vascular density of the superficial and deep capillary plexus.

Intraoperative Optical Coherence Tomography in Vitreoretinal Surgery.

Introduction: The objective of this article is to provide an overview of the current situation with the use of intraoperative optical coherence tomography (iOCT), and to present our own experience with this technology.

Methodology: retrospective evaluation of case reports of typical pathologies of the retina which were resolved by means of standard pars plana vitrectomy (PPV) with the use of intraoperative optical coherence tomography (iOCT) integrated into the surgical microscope OPMI Lumera 700 / Rescan 700 (Zeiss). Auxiliary techniques: best corrected visual acuity (BCVA) was tested on ETDRS tables, biomicroscopy was performed with a 78D lens and optical coherence tomography (OCT) with a Zeiss Cirrus instrument.

Microincision 25G pars plana vitrectomy with peeling of the inner limiting membrane and air tamponade in idiopathic macular hole.

Purpose: To evaluate the success of a mini-invasive technique for operation of idiopathic macular hole (IMH).

Methods: We retrospectively examined 29 patients (30 eyes) in whom 25-G pars plana vitrectomy (PPV), peeling of the inner limiting membrane (ILM), and application of air tamponade were performed. The group of the patients included 7 males and 22 females (76%), age range 57-79 years (median 70).

Re-operation of idiopathic macular hole after failed initial surgery.

Background: Persistent idiopathic macular hole (IMH) after initial pars plana vitrectomy (PPV) appears in approx. 12% of cases. It is, therefore, one of the most common complications.

Effects of treatment change in patients with neovascular age-related macular degeneration; results from the Czech National Registry.

Aims: To determine the effectiveness of second line treatments in patients with neovascular AMD who did not respond adequately to primary treatment.

Methods: Retrospective, multicentre assessment. The frequency of primary treatment failure and outcomes of subsequent secondary treatment were assessed according to the type of primary treatment, type of CNV and change in BCVA over a 12 month period.

Haemorheopheresis could block the progression of the dry form of age-related macular degeneration with soft drusen to the neovascular form.

Purpose: To evaluate the influence of haemorheopheresis on anatomical and functional findings in patients with soft-drusen maculopathy.

Methods: We investigated 29 eyes (16 patients) and randomized 25 eyes (16 controls) with soft-drusen maculopathy [soft, confluent and reticular drusen, drusenoid retinal pigment epithelium detachment (RPED)]. Each patient received a series of eight haemorheophereses (cascade filtration of 1.

[Results of transpupillary thermotherapy by patients with age-related macular degeneration 6 months after treatment (pilot study)].

We demonstrated the effectiveness of transpupillary thermotherapy (TTT) for the treatment of choroidal neovascularization (CNV) by patients with age- related macular degeneration (ARMD). CNV secondary to ARMD is a leading case of vision loss in patients older than 50 years. TTT is new promising method for the treatment CNV by ARMD.

[Macular hole--contemporary knowledge and possibilities of treatment].

Macular hole is a disease of the central area of the retina - site of the sharppest vision. Signs of this can be metamorphopsia and different degree of loss of the central vision. More than 100 years didn't exist succesfull treatment but knowledges of that disease have been started since 19 century.

[Age-related macular degeneration--contemporary possibilities of treatment].

Age-related macular degeneration (AMD) is a complex multifactorial disease, that affects the central region of the retina. AMD is a leading cause of blindness among people over 50 years of age in the industrialized world. Two types of macular degeneration exist, the "dry" form and the "wet-neovascular" form.